Stockreport

Inhibikase Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]

Inhibikase Therapeutics, Inc.  (IKT) 
PDF Cash Position: As of September 30, 2025, cash, cash equivalents and marketable securities were $77.3 million as compared to $97.5 million as of December 31, 2024. Mor [Read more]